An Economic Analysis between Entecavir and Lamivudine for the Treatment of Chronic Hepatitis B in Hong Kong

Journal of Gastroenterology and Hepatology, 04/30/2012

Based on the recommended cost–effectiveness threshold of World Health Organization, entecavir is considered cost–effective compared with lamivudine in treating chronic hepatitis B (CHB) in Hong Kong when long term medical consequences were considered.

Print Article Summary Cat 2 CME Report